Table 7.

Summary for the therapies analyzed including the association between bundle use and their administration, the strength of recommendation and quality of evidence supporting their use in septic shock based on the GRADE system,^a and whether randomized controlled trials (RCT) are under way or planned to determine the effectiveness of these therapies in septic shock

Therapy	Consistent Association Between Bundle Use and Administration of Therapy	SSC 2008 Guidelines Grade		On-going or Planned RCTb
		Recommendation	Quality of Evidence
Antibiotics
Rapid antibiotics	Yes	Strong	Moderate	None
Appropriate   antibiotics	Yes	Strong	Moderate	None
Fluids for CVP   8–12 mm Hg	No	Strong	Low	ProCESS, ARISE, ProMISE
Vasopressors for MAP   ≥65 mm Hg	No	Strong	Low	ProCESS, ARISE, ProMISE
Inotropes for Scvo2   ≥70%	No	Weak	Low	ProCESS, ARISE, ProMISE
PRBC for ScvO2   ≥70%	No	Weak	Low	ProCESS, ARISE, ProMISE
Corticosteroids	No	Weak	Low	HYPRESS, APROCCHS
rhAPC	No	Weak	Moderate	PROWESS-SHOCK, APROCHHS

CVP, central venous pressure; MAP, mean arterial pressure; PRBC, packed red blood cells; rhAPC, recombinant human activated protein C.

^aThe GRADE system as employed in the SSC guidelines (31);

^bsee Table 8 for details regarding these trials.